All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F07%3A00001864" target="_blank" >RIV/60162694:G44__/07:00001864 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants

  • Original language description

    The immunogenicity and reactogenicity of primary vaccination at 3, 4 and 5 months and boosting at 12-18 months with a new DTPw-HBV vaccine was compared with either licensed DTPw and HBV vaccines given separately or a licensed DTPw-HBV combination (Tritanrix-HepB) in this randomized, partially double-blind primary vaccination and single-blind booster vaccination study in healthy infants (n = 239; Trial DTPw-HBV-001/004). One month after primary vaccination with the new DTPw-HBV vaccine, seroprotection against diphtheria, tetanus, hepatitis B and vaccine response to B. pertussis was seen in 100%, 98.7%, 94.9% and 98.7% of subjects, respectively, compared to 100%, > or =98.5%, 89.2% and 92.2% of subjects in the comparator groups, respectively.

  • Czech name

    Imunogenicita a reaktogenita nové DTPw-HBV vakcíny v primárním a booster

  • Czech description

    Imunogenita a reaktogenita primárního očkování ve 3., 4. a 5. měsíci a posilované dávky ve 12-18 měsících nové DTPw-HBV vakcíny ve srovnání s licencovanoui DZPw-HBV vakcínaou aplikovanou oddělneně nebo licencovanou DTPw-HBV kombinací (Tritanrix-HepB). Vtéto randomizované, částečně dvojitě slepé primární očkovací a jednoduše zaslepené posilovací vakcinační studii u zdravých kojenců (n=239; Trial DTPw-HBV-001/004). Měsíc po základním očkování novou DTPw-HBV vakcínou bylasledována seroprotekce pro difeterii tetanu, hepatitidě B a proti pertussi ve 100 %, 98,7 %, 94,9 % a 98,7 % subjektů, respektive ve srovnání s kontrolní skupinou se 100 %, 98,5 %, 89,2% a 92,2 %.

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FN - Epidemiology, infection diseases and clinical immunology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    Z - Vyzkumny zamer (s odkazem do CEZ)

Others

  • Publication year

    2007

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Human Vaccines

  • ISSN

    1554-8600

  • e-ISSN

  • Volume of the periodical

    3

  • Issue of the periodical within the volume

    4

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    6

  • Pages from-to

    121-126

  • UT code for WoS article

  • EID of the result in the Scopus database